SK bioscience, a South Korea-based vaccine and biotech company, announced on Wednesday that it has signed a development licensing agreement with Hilleman Laboratories, a Singapore-based vaccines and biologics research and development company that said it is committed to improving vaccine accessibility and affordability for low- and middle-income countries.
The contract has been signed for joint development of a second-generation Zaire Ebola virus vaccine.
Hilleman Laboratories and SK bioscience will collaborate on the development of an improved second-generation Zaire Ebola virus vaccine candidate with the goal of increasing production process productivity and improving product thermostability that would potentially help increase the global Ebola vaccine supply and help expand access.
SK bioscience will acquire unique expertise and know-how for use of rVSV (recombinant Vesicular Stomatitis Virus Vector) technology platform, in close collaboration with Hilleman Laboratories with the potential to jointly develop other vaccines against a variety of viral infectious diseases.
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
Technavio predicts increase in global peptide therapeutics market size
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
SCG Cell Therapy's SCG142 IND application receives US FDA approval
EDX Medical to distribute cResponse cancer assay in UK and Nordics
Scancell Holdings announces evaluation agreement with major biotechnology company
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
YS Biopharma repays USD40m loan facility
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib